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Background: Adhesion of Mycoplasma pneumoniae (M. pneumoniae) to host epithelial cells requires several adhesin
proteins like P1, P30 and P116. Among these proteins, P1 protein has been inedited as one of the major adhesin
and immunogenic protein present on the attachment organelle of M. pneumoniae. In the present study, we
scanned the entire sequence of M. pneumoniae P1 protein to identify the immunodominant and cytadherence
region(s). M. pneumoniae P1 gene was synthesized in four segments replacing all the UGA codons to UGG codons.
Each of the four purified P1 protein fragment was analyzed for its immunogenicity with anti-M. pneumoniae M129
antibodies (Pab M129) and sera of M. pneumoniae infected patients by western blotting and ELISA. Antibodies were
produced against all the P1 protein fragments and these antibodies were used for M. pneumoniae adhesion,
M. pneumoniae adhesion inhibition and M. pneumoniae surface exposure assays using HEp-2 cells lines.
Results: Our results show that the immunodominant regions are distributed throughout the entire length of P1
protein, while only the N- and C- terminal region(s) of P1 protein are surface exposed and block cytadhesion to
HEp-2 cells, while antibodies to two middle fragments failed to block cytadhesion.
Conclusions: These results have important implications in designing strategies to block the attachment of
M. pneumoniae to epithelial cells, thus preventing the development of atypical pneumonia.Background
Mycoplasmas are the smallest known self-replicating pro-
karyotes originally isolated from bovine pleuropneumonia
and are also referred as pleuropneumonia like organisms
(PPLO). A key characteristic of mycoplasma is the lack of a
cell wall, which allows exchange of different components
between the host membrane and the M. pneumoniae
membrane after adhesion [1,2].M. pneumoniae is a human
pathogen that colonizes the ciliated upper and lower
respiratory tract, causing atypical pneumonia. M. pneumo-
niae is also found to be associated with other respiratory
tract infections such as tracheobronchitis, bronchiolitis,
croup, Acute Respiratory Distress Syndrome (ARDS),
Guillain-Barre Syndrome (GBS), stroke and less severe
upper respiratory tract infections in older children as well* Correspondence: drramach@gmail.com; pawanmal@gmail.com
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reproduction in any medium, provided the oras in young adults [3-7]. Adherence of M. pneumoniae to
the human host respiratory epithelium is a prerequisite for
the colonization and subsequent induction of disease [4,8].
It attaches to ciliated epithelial cells in the respiratory tract,
where it induces ciliostasis that protects the M. pneumo-
niae from removal by the mucociliary clearance mechan-
ism of the host [9]. M. pneumoniae is elongated and
consists of a longer tail-like rear end, a thicker body part
and a frontal attachment organelle.
Cytadherence requires a complex interaction of several
M. pneumoniae proteins present on the attachment
organelle, including the adhesins P1 (170 kDa), P30
(30 kDa), and P116 (116 kDa) and proteins HMW1 to
HMW3, as well as proteins A, B and C [4,10-15]. Pro-
tein P1 and P30 appear to be directly involved in recep-
tor binding [8,16]. The HMW proteins and proteins A,
B, and C are accessory proteins as they are not adhe-
sins, but are required for proper attachment. The P1
protein, which is mainly concentrated at the tip of apical
organelle, is one of the major adhesins in M. pneumoniaeral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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virulence capabilities [17,18]. In addition, treatment of M.
pneumoniae infection with anti-P1 antibodies has been
shown to effect the gliding speed of M. pneumoniae, thus
hampering the mobility of the bacterium and possibly its
ability to find suitable host adhesion receptors [19]. Be-
sides its role in M. pneumoniae cytadherence, P1 antigen
is an important immunogen and is also being developed
as defined and specific antigen for the serodiagnosis of M.
pneumoniae infection [20]. Previous reports and we have
shown that a C-terminal region of P1 antigen can compar-
ably diagnose M. pneumoniae infection taking the Serion-
Virion ELISA as the standard [14,21]. Serum samples from
patients suffering from M. pneumoniae infection have also
been shown to bind the peptide fragments located in the
middle of the ~170 kDa P1 antigens [22].
Since P1 is one of the major surface molecules on the
apical organelles of M. pneumoniae, a number of studies
have been performed to determine its immunogenicity
as well as to characterize its role in adhesion/cytadher-
ence. Using λgt11 recombinant DNA expression library
of M. pneumoniae, Dallo et al. for the first time identi-
fied cytadherence (epitopes) at the C-terminal region of
P1 gene [23]. Subsequently, in two independent studies
based on topological mapping of the P1 binding sites,
Gerstenecker et al. and Opitz et al. identified adherence
associated region(s) across the length of P1 gene [11,24].
Jacobs et al. further defined immunodominant epitopes
of 338 amino acids between leucine 801 and leucine
1139 residues [25]. In 2002, Svenstrup et al. expressed
P1 fragments lacking the tryptophan codon which codes
for a stop codon in M. pneumoniae and identified adhe-
sion epitopes in the C-terminal part of M. pneumoniae
P1 gene using monospecific antibodies [14].
Although these above mentioned studies identified few
adhesion/cytadherence segment(s) in M. pneumoniae P1
protein, a systematic study defining the region(s) in-
volved in these processes across the entire length of P1
protein is lacking, therefore leading to contradicting
results. One of the main reasons for the lack of a sys-
tematic study is the presence of 21 UGA codons, which
makes it difficult to express this protein or its fragments
in heterologus systems such as Escherichia coli or mam-
malian systems. To circumvent this problem, PCR-based
site-directed mutagenesis may have been one of method
to replace TGA codons in P1 gene as mentioned by
Hames et al. [26], but we decided to synthesize the
entire P1 gene into four different fragments by codon
optimization. This included the N-terminal (P1-I) frag-
ment, two middle fragments P1-II and P1-III and a
C-terminal (P1-IV) fragment, which have been sug-
gested to be immunodominant and to act as adhesins
[14,21,25,27]. All these fragments were cloned and
expressed in an E. coli system [28-30]. The immunologicaland cytadherence characterization of all the four P1
protein fragments identified specific cytadherence re-
gions. These results will enable to define strategies for
the development of drug/vaccine against M. pneumo-
niae infection.
Results
Cloning, expression and purification of P1 gene
fragments
Four fragments of the M. pneumoniae P1 gene, i.e., P1-I,
P1-II, P1-III, & P1-IV (Figure 1), were amplified by PCR,
cloned in expression vector pET28b and expressed in
E. coli BL21(DE3) cells. The expressed proteins were
analyzed on SDS-PAGE. As shown in Figure 2A, four pro-
teins of molecular weights: ~39 kDa, ~38 kDa, ~73 kDa,
and ~43 kDa were induced and they were mainly
expressed in inclusion bodies. The expressions of re-
combinant proteins were further confirmed by western
blot analysis using anti-6XHis antibody (Figure 2B i & ii).
The expressed proteins were purified up to near homo-
geneity on a Ni2+-NTA column (Figure 2C). Fractions
that contained single band for each of the recombinant
protein were pooled, dialyzed and further characterized.
The expressed and purified proteins reacted nicely with
anti-6XHis antibody (Figure 2D).
Recombinant rP1-I, rP1-II, rP1-III and rP1-IV proteins are
immunogenic
High antibody responses were seen against each of the
four recombinant proteins. The time course response
for each of the recombinant proteins showed that the
antibody titers gradually increased after first and sec-
ond booster and peaked after the second boost. An
additional figure file [see Additional file 1] shows the
time dependent response for recombinant P1-I protein.
Almost similar antigenic responses were observed for
other three P1 protein fragments (data not shown).
The end point titers for each protein were > 1 × 105.
Western blotting for all the four recombinant proteins
with their respective antibodies confirmed the specifi-
city of each antibody. All these antibodies showed
major reactivity with ~170 kDa band of P1 protein in
M. pneumoniae lysate by ELISA (Figure 3B) and western
blotting. Anti-P1 antibodies also reacted with few add-
itional bands in M. pneumoniae lysate. These additional
bands probably represent the degraded P1 protein bands
(Figure 3A). No cross reactivity was observed between
each of the four antibodies (Figure 3C & 3D). Almost
similar reactivity was observed with two other P1 protein
fragments rP1-II & rP1-III (data not shown). These results
indicated that all the four P1 protein fragments are
immunogenic and antibodies are specific as they only
recognized the corresponding protein fragment. Pre-
bleed and control rabbit sera showed no reactivity with
Figure 1 Schematic representation of M. pneumoniae M129 P1 gene and its four gene fragments; P1-I, P1-II, P1-III and P1-IV. Each bar
represents the position of UGA codons that codes for tryptophan. To express these fragments, UGA codons were modified to UGG. Fragments
were amplified using a set of forward (F) and reverse primers (R).
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itional figure file [see Additional file 2] shows the re-
activity of each protein fragment with pre-bleed sera.
Recombinant rP1-I, rP1-II, rP1-III and rP1-IV proteins were
recognized by anti-M. pneumoniae antibody and by sera
of M. pneumoniae infected patients
All the four recombinant proteins were analyzed for their
reactivity to anti-M. pneumoniae antibody and pooled sera
of M. pneumoniae infected patients. To do so, 1 μg of
each recombinant protein was loaded on SDS-PAGE gel
(Figure 4A-I) and the proteins were blotted to nitrocellu-
lose membrane. As shown in Figures 4A-II & III, all the
four proteins showed similar reactivity with either of the
two sera. We next compared the reactivity of the four
recombinant proteins with fifteen and twenty-five sera of
M. pneumoniae infected patients by western blot analysis
and by ELISA respectively. Figures 4B & 5A shows the
reactivity of the recombinant proteins with sera of M.
pneumoniae infected patients. Similar reactivity was seen
for each of the four recombinant P1 protein fragments,
thereby suggesting that the immunodominant regions are
distributed across the entire length of P1 protein.
M. pneumoniae adhesion and surface exposure assays
reveal that P1-I and P1-IV regions are surface exposed.
For the adhesion assay, HEp-2 cells were infected with
M. pneumoniae and methanol fixed before exposing
them with each of the four anti-P1 antibodies; Pab (rP1-I),
Pab (rP1-II), Pab (rP1-III), and Pab (rP1-IV) antibody. The
bound antibodies were detected with an FITC-conjugated
goat anti-rabbit immunoglobulin. As shown in Figure 6
(A-E), Indirect immunofluorescence microscopy analysis
showed that the antibodies, Pab (rP1-I and Pab (rP1-IV
were able to identify M. pneumoniae bound to the HEp-2
cells, while other two antibodies, Pab (rP1-II) and Pab
(rP1-III) failed to identify the bound organism to HEp-2
cells.To detect the accessibility of the antibodies on the sur-
face of the cytadhering M. pneumoniae, the primary anti-
bodies were added before fixation with methanol. The
bound primary antibodies were detected with FITC-
conjugated goat anti-rabbit IgG antibody followed by
immunofluorescence microscopy. As seen in the case of
adhesion detection assay, only the antibodies Pabs, rP1-I
and rP1-IV were able to detect cytadhering M. pneumo-
niae, while no fluorescence was observed when antibodies
Pabs, (rP1-II) and (rP1-III) were used (Figure 6 (F-J).
M. pneumoniae adhesion inhibition assay
To examine the ability of each of the specific antibodies
to block M. pneumoniae binding to HEp-2 cells, each
of the four antibodies were diluted in four different
concentrations 1:50, 1:100, 1:200 and 1:500 (200, 100,
50 and 20 μg/ml respectively). The diluted antibodies
were incubated with the M. pneumoniae before infec-
tion with the HEp-2 cells. The M. pneumoniae attached
to the HEp-2 cells were visualized by anti-M. pneumoniae
sera and secondary FITC-conjugated goat anti-rabbit
IgG antibody. Among these four specific antibodies,
Pab (rP1-I) and Pab (rP1-IV) inhibited the adhesion of
M. pneumoniae to the HEp-2 cells (Figures 7E-H & I-L).
The inhibition was maximum at highest concentration of
antibody (1:50) and inhibition decreased as concentration
of antibodies decreased and almost no inhibition were
seen with the minimum concentration of antibody (1:500
dilution). In an independent experiment, we also per-
formed DAPI staining to confirm adhesion inhibition by
Pab (rP1-I) and Pab (rP1-IV) antibodies [see Additional
file 3]. Importantly, antibodies; Pab (rP1-II) and Pab
(rP1-III) failed to block the M. pneumoniae adhesion to
HEp-2 cells even at the maximum antibody concentra-
tion (1:50 dilution) (Figures 7M & N). Taken together,
these results suggested that P1-I and P1-IV regions of
M. pneumoniae P1 protein are surface exposed and are
involved in cytadherence.
Figure 2 SDS-PAGE and Western blot analysis of recombinant M. pneumoniae P1 proteins fragments. (A) Coomassie blue stained
SDS-PAGE analysis of rP1-I, rP1-II, rP1-III and rP1-IV in E. coli extract. The fragments were expressed in pET28b vector and protein production was
induced with IPTG in E. coli. (B) Western blot analysis of induced and uninduced P1 protein fragments rP1-I, rP1-II, rP1-IV (i) and rP1-III (ii), showing
reactivity with anti-6X His antibody. (C) Coomassie blue stained SDS-PAGE analysis of Ni2+-NTA purified P1 protein fragments; rP1-I, rP1-II, rP1-III
and rP1-IV. (D) Western blot analysis of purified P1 protein fragments rP1-I, rP1-II, rP1-III and rP1-IV showing reactivity with anti-6X His antibody.
Lane Marker: Molecular mass marker (kDa); Arrows indicate position of expressed protein.
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The human respiratory pathogen M. pneumoniae adheres
to erythrocytes/respiratory epithelial cells. P1 has been
shown to be a major adhesion protein [31-34]. A number
of studies using synthetic peptides and monoclonal anti-
bodies against the native P1 protein have illustrated that
the P1 epitopes are involved in the adhesion and immune-
recognition; however a complete topological mapping of
P1-adhesin is still lacking [12,25,27,35]. In the present
study, we segmented the entire P1 gene in four regions;
P1-I (1069 bp), P1-II (1043 bp), P1-III (1983 bp) & P1-IV
(1167 bp) beginning from start residue, ATG and ending
with the stop codon. These segments were synthesized bycodon optimization replacing all the UGA codons to UGG
codons. The P1 fragments were expressed in E. coli system
and all these fragments were expressed in inclusion bod-
ies. A protocol was developed to purify these protein frag-
ments to near homogeneity and to obtain these proteins
in large amount.
The testing of P1 protein fragments with anti-M.
pneumoniae sera and sera of M. pneumoniae infected
patients revealed that all these protein fragments were
recognized by these sera, thereby suggesting that the
immunodominant regions are distributed across the
entire length of the protein. These results are in agree-
ment with a number of previous reports that showed
Figure 3 Western blot and ELISA analysis of M. pneumoniae lysate and Cross reactivity of Pab (rP1-I) and Pab (rP1-IV). Reactivity of P1
(170 kDa) with anti-P1 protein fragments antibody Pab (rP1-I), Pab (rP1-II), Pab (rP1-III) & Pab (rP1-IV) rose in Rabbit by western blotting (A) and by
ELISA (B). (C) & (D) Immuno blot analysis of rP1-I, rP1-II, rP1-III and rP1-IV fragments with Pab (rP1-I) and Pab (rP1-IV) showing their cross reactivity
with respective sera. Lane Marker: Molecular mass marker (kDa).
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middle and C-terminal segments of P1 protein [21,23,
25,27]. A number of previous reports have shown the
presence of immunodominant epitopes usually in the
C-terminal of M. pneumoniae P1 protein [21,23,36], but
few reports also showed immunodominant regions in
the middle and extreme N-terminal [25,27]. A compara-
tive summary of these results is presented in additional
figure file 4 [see Additional file 4]. However, our’s is the
first study that systematically scanned the full P1 pro-
tein for their immunodominant and cytadherence.
Since P1 protein is considered to be the major ligand
mediating attachment, we next tested the ability of the
antibodies raised against the four P1 fragments for adhe-
sion detection, surface exposure and adhesion inhibition
assays to identify the cytadherence regions. Previously, a
number of studies have identified a few M. pneumoniae
P1 regions involved in cytadherence. Trypsinization of
M. pneumoniae P1 protein and ability of various frag-
ments or peptides so generated to block cytadherence
provided first evidence for the role of P1 protein in
cytadherence [4]. Baseman et al., later showed that thetreatment of M. pneumoniae with protease blocked its
adherence to tracheal explants which was restored when
P1 was re-generated [32]. Role of M. pneumoniae P1
protein in cytadherence was further substantiated by a
study where pre-treatment of M. pneumoniae with anti-
serum directed against the P1 protein blocked its cytadher-
ence to hamster tracheal ring up to 80% [37]. Gerstenecker
and Jacobs [11] and Opitz and Jacobs [24], showed the
involvement of N-terminal, middle and C-terminal seg-
ment of M. pneumoniae (P1) as well as M. genitalium
(MgPa) in cytadherence. Although a number of above
mentioned studies have highlighted the role of M. pneu-
moniae P1 protein in cytadherence, however a system-
atic study spanning the entire length of P1 protein is
missing. We performed a systematic analysis of surface
exposure and cytadherence region(s) for M. pneumo-
niae P1 protein fragments spanning the entire length.
Our results showed that the antibodies against P1-I and
P1-IV corresponding to N- and C- terminal regions of
P1 protein recognized the surface of adhesive mycoplas-
mas and blocked their attachment when mycoplasmas
were pre-incubated with these antibodies. Based on the
Figure 4 Recombinant P1 protein fragments are recognized by anti-M. pneumoniae antibody and by sera of M. pneumoniae infected
patients. (A) (I) Coomassie blue stained SDS-PAGE analysis of purified M. pneumoniae P1 protein fragments; rP1-I, rP1-II, rP1-III and rP1-IV. Immuno
blot analysis of purified P1 protein fragments; rP1-I, rP1-II, rP1-III and rP1-IV using anti-M. pneumoniae antibody (II) and using pooled sera of
M. pneumoniae infected patients (III). (B) Immuno blot analysis of purified M. pneumoniae P1 protein fragments rP1-I, rP1-II, rP1-III and rP1-IV with
several sera of M. pneumoniae infected patients. PM: Prestained protein marker; PC: positive control; NC: Negative control; Numbers over the blot
indicate serial number of sera of M. pneumoniae infected patients tested for these experiments.
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ence regions are located in the N- terminal and C- ter-
minal regions. Interestingly, Pab (rP1-II) and Pab (rP1-III)
antibodies failed to block the cytadherence. The finding of
an attachment regions located in the C-terminal part of
M. pneumoniae P1 protein was consistent with a number
of previous studies [11,14,23,24,38,39]. Summary of the
various P1 cytadherence mapping regions is presented in
additional figure file 5 [see Additional file 5].
Conclusions
Present study describes a systematic approach to delin-
eate the immunodominant and cytadherent regions
across the entire length of M. pneumoniae P1 protein.
Our results showed that the immunodominant regions
are present in several positions across the entire length
of the M. pneumoniae P1 protein, while the N- terminal
and C- terminal regions of the protein are surface ex-
posed and antibodies to these two regions significantly
block the adhesion. This data plus data from earlier ob-
servations thus confirms the functional significance for
M. pneumoniae P1 protein in adhesion and immunodi-
agnosis. These results may have important implications
in the development of tools for anti-Mycoplasma drug/
vaccine development.Methods
Ethics statement
The protocol of this study was approved by Institutional
Animal Ethics Committee (IAEC), AIIMS, New Delhi.
Human blood samples used in this study were received
from an already-existing collection approved by the In-
stitution Ethics Committee (IEC), AIIMS, New Delhi.
Mycoplasma pneumoniae, HEp-2 cells and culture
conditions
The lyophilized ampoule of M. pneumoniae standard
strain (M129 strain; National Collection of Type Cul-
tures, London, United Kingdom) was reconstituted in
Edward Hayflick medium containing PPLO basal broth
that was supplemented with 1% glucose (Difco) as the
carbon source and 0.0002% phenol red as the indicator.
Tissue culture flasks (Nunc, Roskilde, Denmark) were
incubated at 37°C aerobically and inspected daily. An
exponential growth phase was indicated by a change in
color of the medium from red to orange. Cells were har-
vested at this stage, washed in phosphate-buffered saline
(PBS), centrifuged, and the pellet was stored at −70°C.
The organism was confirmed by sub-culturing 0.2 ml of
the broth culture on PPLO agar plates (Borosil). Plates
were incubated at 37°C in 5% CO2 incubator and were
Figure 5 Comparative ELISA analysis of recombinant P1 protein fragments with sera of M. pneumoniae infected patients. Reactivity of
purified M. pneumoniae P1 proteins fragments with 25 sera of M. pneumoniae infected patients by ELISA (A), with 16 healthy patient sera (B) and
average values of both A & B (C). Number on top of column indicates serial number of sera of M. pneumoniae infected patients tested for
these experiments.
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by Dienes staining and PCR.
The human laryngeal carcinoma cell line, HEp-2 (ATCC,
MD, USA), was cultured in TTP tissue-culture flasks
(Nunc, Roskilde, Denmark) containing RPMI-1640 medium
(Gibco BRL, Grand Island, NY, USA) with 25 mM Hepes-
buffer (0.01 M N-2-hydroxyethylpip- erazine-N9-2-
ethanesulphonic acid, 0.15 M NaCl, pH 7.2), sodium
bicarbonate, fetal calf serum 10%, 200 μg ml−1 genta-
micin and 2 mM glutamine, pH 7.2. HEp-2 cell was
maintained by loosening the cells with PBS containing
trypsin 0.25% and EDTA 0.02% and new flask was
seeded [14].
Synthesis and PCR amplification of P1 gene fragments
Entire M. pneumoniae M129 P1 gene was synthesized in
four fragments; N-terminal P1-I (1069 bp), two middle
fragments P1-II (1043 bp) and P1-III (1983 bp), and C-terminal P1-IV (1167 bp) fragments by codon optimization
replacing 21 UGA to UGG codons (Entelechon GmbH,
Germany). To express these P1 gene fragments, four sets of
primers were designed, each having two restriction sites
either at 5’end or 3’ end; NcoI and Bam HI were inserted at
5’ end or Hind III and Sal I were inserted at 3’ end. Table 1
shows the sequence of each primer. PCR was performed in
a 50 μl of reaction mixture containing 1U of Taq polymer-
ase, 1X PCR buffer, 200 μM deoxynucleotide diphosphates,
1.5 mM MgCl2, 10 pmol of each primer and template
DNA. The reaction conditions were standardized at
an initial denaturation of 94°C for 5 min, followed by
denaturation at 94°C for 30 sec, annealing at 60°C for
30 sec and extention at 72°C for 1 min for 30 cycles. A
final extention was done at 72°C for 5 min. All the four
amplified fragments were cloned in pGEM-T easy clon-
ing vector. Cloned fragments were confirmed by restric-
tion digestion and sequencing.
Figure 6 IFM adhesion assay of M. pneumoniae (A-E). The M. pneumoniae attached to the HEp-2 cells were detected by either
anti-M. pneumoniae antibody or antibodies rose in rabbits. The detecting antibodies were added after fixation with methanol. (A) anti-M. pneumoniae
antibody (positive control), (B) Pab (rP1-I), (C) Pab (rP1-II), (D) Pab (rP1-III), (E) Pab (rP1-IV). IFM surface exposure assay of M. pneumoniae (F-J). In this
assay the detecting antibodies were added before the methanol fixation. (F) anti-M. pneumoniae antibody (positive control), (G) Pab (rP1-I), (H) Pab
(rP1-II), (I) Pab (rP1-III), (J) Pab (rP1-IV). Negative controls: (K) mycoplasmas alone (Without Pabs), (L) Pabs alone (Without mycoplasmas). Bar, 2 μm.
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fragments
For the expression, sub-cloning of the P1 gene fragments
was done in NcoI and Hind III linearised pET28b vector.
Ligation mixtures were used to transform BL21(DE3) and
transformants were selected on kanamycin (25 μg ml−1)
plates. Plasmid DNA was extracted from overnight cul-
tures and subjected to restriction digestion to check the
inserts. BL21(DE3) cells containing the recombinant plas-
mids were cultivated in 5 ml of LB broth containing kana-
mycin at 37°C with shaking (250 rpm) until the optical
density (OD) reached 0.4 to 0.6. Protein expression was
induced by 1 mM IPTG (isopropyl-β-D-thiogalactopy-
ranoside; Sigma). After 5 h of induction at 37°C, bacterial
cells were pelleted by centrifugation and the expression of
each protein was analyzed on sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gel.
Sub-cellular localization studies were carried out to
analyze the expression of protein fragments in E. coli cells.
Proteins were found to be expressed in the inclusion bod-
ies. For the preparation of inclusion bodies E. coli cells were
disrupted by sonication in Tris-buffer (0.05 M Tris, pH 8.0,
and 0.3 M NaCl) with 1 min pulses at 1 min intervals 10
times using mini probe (LABSONICR M, Sartorius Stedim
Biotech GmbH, Germany). The soluble and insolublefractions were separated by centrifugation at 14,000 × g
at 4°C for 30 min and were analyzed by SDS-PAGE.
To purify the all four P1 fragments, a protocol devel-
oped by Jani et al. was followed [40]. Briefly, one liter of
E. coli culture cells expressing each of the protein frag-
ments was grown and induced with 1 mM IPTG. After
the induction, the bacterial pellets were obtained by cen-
trifugation and then suspended in 1/20 volume of sonic-
ation buffer; 0.05 M Tris (pH 8.0), 0.3 M NaCl and 1%
Triton X-100. The cell suspension was sonicated and the
suspension was centrifuged at 14,000 × g for 30 min at
4°C. Pellets were washed 4 times with Tris-buffer without
Triton X-100 and resuspended in CAPS (N-cyclohexyl-3-
amino propanesulfonic acid, pH 11) buffer containing
1.5% Sarkosin and 0.3 M NaCl. Suspensions were incu-
bated for 30 min at room temperature and were centri-
fuged at 14,000 × g for 10 min at 4°C. Supernatant of
each protein was kept with Ni-NTA+ agarose resin with
constant shaking for 1 h at 4°C. After binding, each
supernatant was packed in four different purification
columns and the resin was washed 4 times with CAPS
buffer (10% imidazole). Bound proteins were eluted with
Tris-buffer (pH 8.0) containing 0.25 M imidazole (Sigma-
Aldrich, USA). Each protein fragments were eluted in
5 ml of buffer collecting in ten different fraction of 0.5 ml
Figure 7 IFM adhesion inhibition assay. M. pneumoniae were pre-incubated with either anti-M. pneumoniae antibodies or antibodies rose
in rabbits in different dilutions (1:50, 1:100, 1:200, 1:500) before infection of the HEp-2 cells. These antibodies were: (A-D) anti-M. pneumoniae
antibody (positive control), (E-H) Pab (rP1-I), (I-L) Pab (rP1-IV), (M) Pab (rP1-II) (N) Pab (rP1-III) (O) Without antibody, (P) pre-immune serum.
Bar, 2 μm.
Table 1 Primer sequence used to amplify all four
fragments of M. pneumoniae M129 P1 gene
Primers Position
(bp)
Sequences 5’ to 3’
F-P1-1 1–21 GGCCATGGGATCCATGCATCAAACCAAAAAAACG
R-P1-1 1051–1069 CCAAGCTTGTCGACCCAAGGAGTTGGTGATCC
F-P1-2 953–974 GGCCATGGGATCCATTAAACGGAGTGAAGAGTCA
R-P1-2 1978–1996 CCAAGCTTGTCGACGTTATTGTGAAAGTAGTA
F-P1-3 1875–1896 GGCCATGGGATCCTTACGCGAAGACCTGCAGCTC
R-P1-3 3840–3858 CCAAGCTTGTCGACCGGCTGGGTACTATGGTC
F-P1-4 3729–3749 GGCCATGGGATCCCTGCACTTGGTGAAACCGAA
R-P1-4 4878–4896 CCAAGCTTGTCGACTGCGGGTTTTTTGGGAGG
The first letter of the primer name denotes the direction of the primer: F
forward; R reverse.
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PAGE gels and fractions containing the recombinant pro-
teins with a high degree of purity were pooled separately.
The pooled protein fractions were extensively dialyzed
against PBS, pH 8.0 and the protein concentration was de-
termined by Bradford method. The eluted recombinant pro-
teins were denoted as rP1-I, rP1-II, rP1-III and rP1-IV for
protein fragments P1-I, P1-II, P1-III and P1-IV respectively.
SDS-PAGE and western blotting
To analyze the expression of all four recombinant pro-
teins, induced and un-induced E. coli pellets from 1 ml
of grown cultures were resuspended in 100 μl of 1× SDS
sample buffer (62.5 mM Tris–HCl, pH 6.8, 10% glycerol,
2.3% w/v SDS, 5% v/v β-mercaptoethanol and 0.05% w/v
bromophenol blue) and boiled for 5 min. The proteins
were resolved on 10% SDS-PAGE gel and subsequently
stained with Coomassie brilliant blue R-250. To ascertain
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ting was performed from E. coli cell extracts. For immuno-
blotting, after separating proteins on SDS-PAGE gel, the
resolved proteins were transferred onto a nitrocellulose
membrane (Sigma-Aldrich, USA) in a trans-blot apparatus
(Mini-PROTEAN III, Bio-Rad, USA). The membranes
were blocked in blocking buffer (5% skimmed milk in
PBS-Tween-20) at room temperature for 2 h. The blots
were washed with PBS-Tween-20 (PBS-T) and incubated
with monoclonal anti-6XHis primary antibody (Sigma-
Aldrich, USA; 1:3,000 dilutions) for 1 h. Blots were subse-
quently washed and incubated with secondary anti-mouse
IgG antibody conjugated with horseradish peroxidase
(1:3,000 dilutions). The blots were developed with 3, 3’-di-
aminobenzidine tetrabenzidine hydrochloride (DAB)-H2O2
(Sigma-Aldrich, USA).
Purified recombinant proteins were analyzed for their
reactivity with anti-M. pneumoniae antibodies (procured
from Public Health Laboratory, London) and sera of
M. pneumoniae infected patients collected from patients
with community-acquired pneumonia who tested positive
for IgG antibodies to M. pneumoniae (Serion Classic
ELISA kit; Serion GmbH, Wurzburg, Germany). The
membranes having purified recombinant P1 protein frag-
ments were blocked with 5% skimmed milk in PBST at
room temperature for 2 h. After washing with PBST, the
blots were incubated with either anti-M. pneumoniae
IgG antibody (1:3,000 dilutions) or with sera of M. pneu-
moniae infected patient (1:50 dilutions) in two independ-
ent experiments. For the negative control, human serum
from healthy patient (1:50 dilutions) was used. These
blots were washed and then incubated with goat anti-
rabbit IgG or goat anti-human IgG antibodies conjugated
with horseradish peroxidase (1:5000 dilutions). The blots
were subsequently developed with 3, 3’-diaminobenzidine
tetrabenzidine hydrochloride (DAB)-H2O2.
Immunization of Rabbits for raising antibodies against P1
protein fragments rP1-I, rP1-II, rP1-III and rP1-IV
To characterize the immunogenic potential of recombin-
ant P1 protein fragments, New Zealand white rabbits
were used for the immunization with the approval of the
Animal Ethics Committee, in accordance with the rules
and regulations set forth by the AIIMS Animal Ethics
Committee. Immunization was carried out with 6 week
old New Zealand white rabbits which were maintained
in the animal facility of AIIMS. Before immunization,
pre-bleed sera were collected from each of these rabbits.
Rabbits were immunized with 200 μg of purified recom-
binant P1 protein fragments (rP1-I, rP1-II, rP1-III and
rP1-IV) emulsified in equal volume (300 μl) of complete
Freund’s adjuvant (CFA, Sigma-Aldrich, USA) intramus-
cularly. Rabbits were subsequently boosted with 200 μg
of same protein fragments emulsified in equal volume(300 μl) of incomplete Freund’s adjuvant (CFA, Sigma-
Aldrich, USA) through the same route on the 28th and
56th day. Each one of the control rabbit was immunized
with complete or incomplete Freund’s adjuvant in PBS
according to the immunization schedule. Blood samples
were collected from each of the rabbit by ear vein punc-
turing on 14, 21, 35, 49 and 63 days. The serum was
separated by centrifugation and stored at −20°C for further
analysis. The rabbit sera were denoted as Pab (rP1-I), Pab
(rP1-II), Pab (rP1-III) and Pab (rP1-IV) respectively. IgG
antibody responses against the recombinant protein frag-
ments were analyzed by ELISA and end point titers were
determined. To confirm the specificity of antisera, western
blot analysis was carried-out for each of the recombinant
protein fragments with each antiserum.
Comparative analysis of recombinant P1 protein
fragments by western blotting
In this experiment, equal amount (1 μg) of purified re-
combinant P1 protein fragments (rP1-I-IV) were run in
two separate SDS-PAGE. SDS-PAGE of all the four puri-
fied P1 protein fragments was transferred to two separate
nitrocellulose membrane to perform western blotting.
After blocking with 5% skimmed milk in PBS-T one mem-
brane was then incubated with primary antibody (pooled
sera of M. pneumoniae infected patients, 1:50) and second
membrane was incubated with primary anti-M. pneumo-
niae antibody (1:3,000 dilutions) for 1 h. After washing
with PBS-T first membrane was incubated with secondary
antibody goat anti-human IgG and second membrane
with secondary antibody goat anti-rabbit IgG conjugated
with horseradish peroxidase (1:5000 dilutions) for 1 h.
The membrane was developed with DAB and H2O2.
Reactivity of recombinant P1 protein fragments to
patient sera
All the four recombinant P1 protein fragments; rP1-I,
rP1-II, rP1-III and rP1-IV were analyzed for their re-
activity to twenty five sera of M. pneumoniae infected
patients and sixteen healthy patient sera using ELISA
assay as well as fifteen sera of M. pneumoniae infected
patients by western blot analysis. Western blot analysis
was performed as described above using equal amount of
recombinant proteins. For the ELISA analysis, 96-well
microplates (Nunc, Roskilde, Denmark) were coated with
50 ng of either of the four P1 protein fragments in 0.06 M
carbonate/bicarbonate buffer (pH 9.6) per well. The plates
were kept overnight at 4°C and next day the well were
washed with PBS-T and blocked with 5% skimmed milk in
PBS-T for 2 h at room temperature. The antigen coated
wells were next incubated with sera of M. pneumoniae
infected patients (1:50 dilutions) for 1 h at 37°C. After
incubation, plates were washed with PBS-T and incubated
with secondary goat anti-human antibody conjugated with
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1 h at 37°C. The enzyme reaction was developed by
addition of TMB/H2O2 substrate (Bangalore Genei) and
was incubated in dark for 30 min at 37°C. The reaction
was stopped with 2 N H2SO4 and the absorbance was
read at 450 nm wavelength using micro-plate ELISA
reader (Bio-Tek Microplate Reader, USA).
M. pneumoniae adhesion assay
HEp-2 cells (5×104 HEp-2 cells ml−1), in RPMI-1640
medium with penicillin (100 U ml−1) 0.05% were added
to 24-well Multi-dish plates (Nunc, Roskilde, Denmark)
using sterile glass cover slips underneath. The plates were
incubated overnight in 5% CO2 at 37°C. Next day, HEp-2
cells in each well were infected with the M. pneumoniae
RPMI-suspension (50 μl well−1) and incubated for 6 h in
5% CO2 at 37°C. The infected HEp-2 cells were fixed in
methanol 100% (1 ml well−1) at −20°C for 1 h and washed
with PBS. To detect the adhering mycoplasmas, 100 μl per
well of each of the primary antibodies anti-M. pneumoniae
antibodies, Pab(rP1-I), Pab(rP1-II), Pab(rP1-III), or Pab
(rP1-IV (1:500 dilutions) were added and were incubated
for 1 h at 37°C. Wells were washed subsequently and later
100 μl of secondary fluorescein isothiocyanate (FITC)-
conjugated goat anti-rabbit IgG (whole molecule, 1:100
dilutions) (Santa Cruz Biotech, USA) was added. The cells
were washed twice in PBS before and after the addition of
antibodies. Cells were subsequently incubated with Evans
Blue diluted 1:10 for 30 min at 37°C. Finally the cells were
washed with double distilled water.
M. pneumoniae adhesion inhibition assay
For the adhesion inhibition assay, protocol developed by
Svenstrup et al. was followed [14]. Briefly, the M. pneu-
moniae suspension (50 μl) was pre-incubated for 2 h at
37°C with 50 μl of anti-M. pneumoniae antibodies, Pab
(rP1-I), Pab (rP1-II), Pab (rP1-III) or Pab (rP1-IV) in
different dilutions (1:50, 1:100, 1:200 and 1:500) before
incubation of the HEp-2 cells. The M. pneumoniae-anti-
bodies suspension (100 μl) was then added to the HEp-2
cells together with 1 ml of RPMI with penicillin and
incubated overnight in 5% CO2 at 37°C. Fixation and
addition of secondary antibodies were carried-out as de-
scribed in the adhesion of M. pneumoniae. To further
confirm the adhesion inhibition, the assay was per-
formed as mentioned above except that DAPI was added
at the end of the assay for further 30 min at room
temperature.
M. pneumoniae surface exposure assay
To detect M. pneumoniae surface protein, the primary
antibodies were added before methanol fixation. Other-
wise, the procedure was the same as described for the
M. pneumoniae adhesion assay.Indirect immunofluorescence microscopy (IFM)
Samples prepared for M. pneumoniae adhesion assay, M.
pneumoniae adhesion inhibition assay and M. pneumo-
niae surface exposure assay were analyzed by IFM using
Olympus BX51upright fluorescence microscope. Before
microscopy analysis, a drop of anti-fade solution (p-phe-
nyldiamine dihydrochloride 1 μg ml−1 in PBS 10% and gly-
cerol 90%, pH 9.0) was placed between the glass cover
slips and the slides.Additional files
Additional file 1: Immune response of P1 protein fragment rP1-I in
rabbits. Bar diagram showing immune responses in four different White
New Zealand rabbits immunized with purified recombinant protein
fragment, rP1-I with complete/incomplete Freund’s adjuvant. Control rabbits
were injected with complete/incomplete Freund’s adjuvant in normal saline
according to the immunization schedule.
Additional file 2: Western blot analysis of recombinant P1 protein
fragments with rabbits pre-bleed sera. P1 protein fragments rP1-I,
rP1-II, rP1-III & rP1-IV were separated on SDS-PAGE and blots were probed
with pre-bleed sera showing no reactivity.
Additional file 3: IFM Adhesion inhibition assay with DAPI staining.
M. pneumoniae were pre-incubated with monospecific antibodies in
different dilutions (1 in 50, 1 in 100, 1 in 200, 1 in 500) before infection of
the HEp-2 cells. M. pneumoniae infected HEp-2 cells were stained with
Evans blue (red) and DAPI (blue). The M. pneumoniae microcolonies at-
tached to HEp-2 cells are detected by (a-d) Pab (rP1-I), (f-i) Pab (rP1-IV)
and (e & j) pre-bleed rabbit sera with FITC conjugated secondary anti-
body (green fluorescence). The nuclear material of M. pneumoniae micro-
colonies were not detected by DAPI staining.
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P1 protein of M. pneumoniae. Comparison of cytadherence regions
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